Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Increases By 16.6%

Aadi Bioscience, Inc. (NASDAQ:AADI) was the recipient of a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 1,100,000 shares, an increase of 16.6% from the March 31st total of 943,100 shares. Currently, 6.3% of the shares of the company are sold short. Based on an average trading volume of 346,800 shares, the days-to-cover ratio is currently 3.2 days.

Aadi Bioscience Trading Up 3.2 %

Shares of NASDAQ:AADI opened at $1.92 on Wednesday. The firm’s 50 day moving average is $2.05 and its two-hundred day moving average is $2.79. The firm has a market capitalization of $47.14 million, a P/E ratio of -0.79 and a beta of 0.62. Aadi Bioscience has a 52 week low of $1.55 and a 52 week high of $8.60.

Aadi Bioscience (NASDAQ:AADI) last issued its earnings results on Wednesday, March 13th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.07. The firm had revenue of $6.33 million during the quarter, compared to analysts’ expectations of $6.46 million. Aadi Bioscience had a negative net margin of 270.04% and a negative return on equity of 52.53%. Analysts predict that Aadi Bioscience will post -2.47 EPS for the current year.

Insider Buying and Selling

In related news, Chairman Neil Desai sold 42,000 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $1.74, for a total transaction of $73,080.00. Following the sale, the chairman now owns 1,453,543 shares in the company, valued at $2,529,164.82. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 101,772 shares of company stock worth $198,819 over the last quarter. 35.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Aadi Bioscience

A hedge fund recently bought a new stake in Aadi Bioscience stock. Decheng Capital LLC purchased a new stake in Aadi Bioscience, Inc. (NASDAQ:AADI) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 526,329 shares of the company’s stock, valued at approximately $1,063,000. Aadi Bioscience makes up about 0.3% of Decheng Capital LLC’s portfolio, making the stock its 22nd biggest position. Decheng Capital LLC owned approximately 2.15% of Aadi Bioscience as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 52.08% of the company’s stock.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.